Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Sponsor
University Hospital, Brest
Study ID
NCT02888496
Status
Completed

Conditions

  • Polymyalgia Rheumatica

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • tocilizumab — DRUG
    3 monthly IV infusions in PMR patients

Study Details

Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.

Key Dates

Start date
Jan 31, 2015
Status verified
Aug 2016
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015

Study Design

Enrollment
40 participants (actual)

Arms

  • Arm: PMR patients
    Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
  • Arm: Healthy controls
    Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease

Primary Outcome Measure

Proportion of blood lymphocyte populations (T cells, B cells, NK cells) [ Time Frame: 6 months ]

Related Studies